Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 3 of 1012345...10...Last »

Hired experts support claims St. Jude heart devices can be hacked

Short-selling firm Muddy Waters said in a legal brief that outside cyber security experts it hired have validated its claim that St. Jude Medical Inc. cardiac implants are vulnerable to potentially life-threatening cyber attacks.

Read More »

FDA Slaps Partial Hold on Bay Area Firm Aduro Biotech’s Cancer Vaccine Trial

The U.S. FDA placed a partial hold on Berkeley, Calif.-based Aduro Biotech’s LADD trials.

Read More »

GSK files shingles vaccine for U.S. approval

GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential $1 billion-a-year seller a step closer to market.

Read More »

Sanders urges Californians to approve drug price ballot measure

Former Democratic presidential candidate Bernie Sanders, in an opinion editorial published in the Los Angeles Times, urged Californians to approve a November ballot measure aimed at reining in pharmaceutical prices.

Read More »

Polio vaccine makers failing to make enough doses: WHO experts

Two companies making vaccines to help the world eradicate polio are failing to produce enough, so many countries should prepare to give lower doses to make stocks last, a group of experts has advised the World Health Organization.

Read More »

Rehab after heart attack tied to longer, not healthier life

Heart attack survivors who participate in cardiac rehabilitation programs may survive longer, but feel no healthier, than they would without this follow-up care, a U.S. study suggests.

Read More »

Indian doctor accused of crimes becomes president of World Medical Association

The World Medical Association (WMA), the top medical-ethics body, installed an Indian doctor facing corruption charges as its president despite controversy surrounding his appointment while legal cases are pending.

Read More »

One Fine Specimen: Where Biopharma Competitiveness Really Begins

Before there are new therapies to set a firm apart, there is a far more fundamental need that competitiveness will ultimately hinge on: high-quality, diversified, annotated human biospecimens.

Read More »

Merck’s Keytruda Wows in Bladder Cancer Trial

Merck & Co. ended a Phase III trial of Keytruda in advanced urothelial cancer because the immuno-oncology drug met its primary endpoint.

Read More »

Alkermes Depression Drug Aces Key Study

Alkermes’ experimental anti-depression drug ALKS-5461 significantly reduced symptoms in major depressive disorder patients not helped by standard treatments.

Read More »

Bernie Sanders, U.S. Rep Cummings seek info on Ariad leukemia drug

Former Democratic presidential candidate Bernie Sanders and U.S. Representative Elijah Cummings issued a letter seeking information from Ariad Pharmaceuticals Inc. on the “staggering” price increases for the company’s leukemia drug.

Read More »

Obama says his departure may fix what ails Obamacare

President Barack Obama said his departure from office in January might be what it takes to begin to heal the political scars over Obamacare and allow for needed fixes to his signature healthcare law.

Read More »

Gilead unveils promising hep C, fatty liver data; setbacks elsewhere

Gilead announced high cure rates across all types of hepatitis C in late-stage studies testing a triple drug combo; another experimental drug showed promise in reducing liver scarring in a mid-stage trial.

Read More »

Roche bid for Avastin follow-on suffers blow with trial failure

Swiss drugmaker Roche’s bid to follow its blockbuster cancer drug Avastin with a newer, better drug took a hit when it announced that an investigational therapy had failed in a study against metastatic colorectal cancer (mCRC).

Read More »

Roche bets on new cancer drugs to offset patent expirations

Roche said strong sales of new medicines like cancer immunotherapy drug Tecentriq would help to sustain the company’s growth as patents on older drugs start to expire.

Read More »

Taking a personal stand on suicide prevention

In January 2013, after a long struggle with severe depression, my boyfriend took his own life. When someone you love commits suicide, there’s no handbook, no rules, no guidance for how to handle it.

Read More »

Rigel’s bleeding disorder drug fails late-stage study

Rigel Pharmaceuticals Inc. said its lead drug to treat a bleeding disorder failed in a second late-stage trial, sending its shares tumbling 32 percent in premarket trading.

Read More »

AbbVie Abandons Arthritis Pact With Ablynx

Ghent, Belgium-based Ablynx announced that it is wrapping up its Phase II trials and starting meetings with U.S. and European regulators about its anti-IL-6R Nanobody, vobarilizumab, in rheumatoid arthritis (RA).

Read More »

Roche third-quarter sales rise 3 percent, confirms outlook

Roche confirmed its full-year 2016 outlook on the strength of robust sales of cancer drugs including Tecentriq, the new immunotherapy that the Swiss company is banking on to counter patent expirations of its older medicines.

Read More »

Pre-teens need only two HPV shots, not three, CDC recommends

Two doses of a vaccine that protects against cervical and several other types of cancer are enough for 11-to 12-year-olds, rather than the previous three-shot regimen, the U.S. Centers for Disease Control and Prevention said.

Read More »

Page 3 of 1012345...10...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom